You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Most frequent potential drug-drug exposures. The classification of a drug-drug exposure was determined by the prescription information for the brand-name drugs

From: Frequency and clinical relevance of potential cytochrome P450 drug interactions in a psychiatric patient population – an analysis based on German insurance claims data

Potential drug-drug exposure Frequency Events per 100 person-years (Poisson exact 95 %–CI) Number of patients with at least one DDE (%) Clinical relevance of a potential interaction (as per prescribing information)
diazepam & omeprazole 52 1.00 (0.74–1.31) 17 (1.39) Omeprazole may increase systemic exposure to diazepam [31]
doxepin & venlafaxine 54 1.03 (0.78–1.35) 15 (1.23) not mentioned
doxepin & paroxetine 44 0.84 (0.61–1.13) 13 (1.06) not mentioned
amitriptyline & omeprazole 58 1.11 (0.84–1.44) 12 (0.98) not mentioned
doxepin & tramadol 51 0.98 (0.73–1.28) 11 (0.90) Tramadol may increase the potential of seizures related to tricyclic antidepressants. Serotonin syndrome may occur [32] [unclear if due to CYP interactions]
amitriptyline & paroxetine 29 0.56 (0.37–0.80) 9 (0.74) Patients taking SSRIs should only be treated with amitriptyline with particular caution [33] [reason not given]
amitriptyline & esomeprazole 31 0.59 (0.40–0.84) 8 (0.66) not mentioned
doxepin & risperidone 95 1.82 (1.47–2.22) 8 (0.66) Mutual reinforcement of the central depressant effect [34]
fluoxetine & omeprazole 11 0.21 (0.11–0.38) 8 (0.66) not mentioned
doxepin & duloxetine 22 0.42 (0.26–0.64) 7 (0.57) not mentioned
    
Sum 1393 26.72 (25.34–28.16) 330